Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
Novel Regimen Outperforms Standard Chemotherapy in HER2 Breast Cancer
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
An ongoing clinical trial of a novel strategy to evaluate new chemotherapy regimens for patients with early-stage breast cancer has identified another neoadjuvant combination therapy worthy of a phase 3 clinical trial involving patients with HER2-positive breast cancer.
Read Article
Approval of First Liquid Biopsy to Detect EGFR Mutations in Lung Cancer Can Improve Patient Outcomes
By
Jessica Miller
Lung Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
The first liquid biopsy used to detect gene mutations that are associated with non–small-cell lung cancer (NSCLC) was approved by the FDA. The cobas EGFR Mutation Test v2 (Roche Molecular Systems), a blood-based companion diagnostic for erlotinib (Tarceva), is indicated as an initial test to detect
EGFR
gene mutations in patients with NSCLC.
Read Article
Updated NCCN Guideline Calls for EGFR Mutations Testing in All Patients with NSCLC
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
Tyrosine kinase inhibitors (TKIs) are the mainstay of therapy for patients with epidermal growth factor receptor (
EGFR
) mutation–positive non–small-cell lung cancer (NSCLC), according to the updated National Comprehensive Cancer Network (NCCN) NSCLC guideline. The NCCN guideline recommends
EGFR
testing as part of a broad molecular profiling in patients with NSCLC.
Read Article
Osimertinib Effective for First-Line Treatment of EGFR Mutation–Positive NSCLC
By
Laura Morgan
Lung Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
The third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib (Tagrisso) targets
EGFR
mutations, including
T790M
. Osimertinib was approved by the FDA in November 2015 for the treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and the
T790M
mutation whose disease progressed during or after EGFR TKI therapy.
Read Article
Tamoxifen or Anastrozole for DCIS? Age and Symptoms Matter
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
April 2016, Vol 7, No 3
Anastrozole and tamoxifen are similarly effective in preventing breast cancer recurrence in postmenopausal women with ductal carcinoma in situ (DCIS). The choice should depend on patient preferences, side-effect profiles, age, and other patient factors, according to 2 studies presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article
Survival Benefit for T-DM1 Confirmed in Metastatic Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
April 2016, Vol 7, No 3
The antibody-drug conjugate trastuzumab emtansine (T-DM1) improved overall survival (OS) compared with physician’s choice of therapy in patients with pretreated HER2-positive metastatic breast cancer, according to the final results of the phase 3 TH3RESA trial, which were presented at the 2015 San Antonio Breast Cancer Symposium.
Read Article
Regular Aspirin Use Reduces the Risk for Prostate Cancer Death
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
March 2016, Vol 7, No 2
The regular use of aspirin reduces the incidence of and risk for death from lethal prostate cancer, according to the results of a large observational study reported at the 2016 ASCO Genitourinary Cancers Symposium. For the purposes of this study, lethal prostate cancer was defined as metastatic disease or prostate cancer–specific death.
Read Article
Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
March 2016, Vol 7, No 2
Increased levels of physical activity after a diagnosis of prostate cancer are associated with significantly better survival, according to the results of a new, large prospective cohort study (Friedenreich CM, et al.
Eur Urol
. 2016 Jan 7. Epub ahead of print).
Read Article
Biomarker Panel May Aid Early Detection of Colorectal Cancer
By
Charles Bankhead
Colorectal Cancer
,
Personalized Medicine
,
Solid Tumors
March 2016, Vol 7, No 2
A panel of 4 blood-derived biomarkers showed promise as an aid to early detection of colorectal cancer (CRC). The panel yielded a negative predictive value exceeding 90% for CRC, the combination of CRC and high-risk adenomas, and colorectal plus other cancers. The biomarker assay demonstrated fair to good performance characteristics, associated with the receiver operating characteristic (ROC) curve ranging between 0.70 and 0.80.
Read Article
Liquid Biopsy Characterizing Circulating Tumor Cells Can Aid Treatment Selection in Prostate Cancer
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
March 2016, Vol 7, No 2
A liquid biopsy using phlebotomy blood samples can identify phenotypes and genomic characteristics of circulating tumor cells that may personalize treatment selection for men with advanced prostate cancer, according to the results of a study presented by Howard I. Scher, MD, Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, NY, at the 2016 ASCO Genitourinary Cancers Symposium.
Read Article
Page 7 of 16
2
3
4
5
6
7
8
9
10
11
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma